



*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

## Revision of PRECAUTIONS

### Candesartan cilexetil/Amlodipine besilate, Candesartan cilexetil/Hydrochlorothiazide, Valsartan/Hydrochlorothiazide, and Losartan potassium/Hydrochlorothiazide

June 3, 2014

#### Non-proprietary Name

- Candesartan cilexetil/Amlodipine besilate
- Candesartan cilexetil/Hydrochlorothiazide
- Valsartan/Hydrochlorothiazide
- Losartan potassium/Hydrochlorothiazide

#### Safety measure

Precautions section should be revised in the package inserts.

In Precautions for concomitant use subsection of Interactions section, the following texts should be added (underlined parts are revised):

#### Angiotensin-converting enzyme inhibitors (ACEIs)

##### Clinical symptoms and measures:

Renal impairment, hyperkalaemia, and/or hypotension may occur. Patients should be carefully monitored for renal function, serum potassium level, and blood pressure.

##### Mechanism and risk factors:

Concomitant use with ACEIs may increase an effect of renin-angiotensin system blockade.

In *Other drugs that have an antihypertensive effect* paragraph of Precautions for concomitant use subsection, 'ACEIs' should be deleted.